Which has higher valuation and earnings, CNTA or AAPG?

Ascentage Pharma Group International has higher revenue and earnings than Centessa Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Centessa Pharmaceuticals $15M 419.94 -$197.53M -$1.79 N/A Ascentage Pharma Group International $82.10M 19.43 -$177.71M N/A N/A

Is CNTA or AAPG more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat Centessa Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Centessa Pharmaceuticals N/A -60.37% -44.17% Ascentage Pharma Group International N/A N/A N/A

Which has higher valuation & earnings, AAPG or RGC?

Regencell Bioscience has lower revenue, but higher earnings than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $82.10M 19.43 -$177.71M N/A N/A Regencell Bioscience N/A N/A -$3.58M N/A N/A

Is AAPG or RGC more profitable?

Company Net Margins Return on Equity Return on Assets Ascentage Pharma Group International N/A N/A N/A Regencell Bioscience N/A N/A N/A

Which has higher valuation and earnings, COGT or AAPG?

Ascentage Pharma Group International has higher revenue and earnings than Cogent Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cogent Biosciences N/A N/A -$328.94M -$2.17 N/A Ascentage Pharma Group International $82.10M 19.43 -$177.71M N/A N/A

Is COGT or AAPG more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -104.27% -54.64% Ascentage Pharma Group International N/A N/A N/A

Which has stronger valuation & earnings, BLTE or AAPG?

Belite Bio has higher earnings, but lower revenue than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Belite Bio N/A N/A -$77.61M -$2.53 N/A Ascentage Pharma Group International $82.10M 19.43 -$177.71M N/A N/A

Is BLTE or AAPG more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -13.14% -12.88% Ascentage Pharma Group International N/A N/A N/A

Which has better valuation and earnings, AAPG or SRRK?

Ascentage Pharma Group International has higher revenue and earnings than Scholar Rock. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $82.10M 19.43 -$177.71M N/A N/A Scholar Rock N/A N/A -$377.94M -$3.59 N/A

Is AAPG or SRRK more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Ascentage Pharma Group International N/A N/A N/A Scholar Rock N/A -163.52% -96.67%

Ascentage Pharma Group International (AAPG) Competitors

$17.08 +0.07 (+0.41%)

Closing price 06/24/2026 03:54 PM Eastern

Extended Trading

$17.14 +0.07 (+0.38%)

As of 04:09 AM Eastern

Compare

AAPG vs. CNTA, RGC, COGT, BLTE, and SRRK

Should you buy Ascentage Pharma Group International stock or one of its competitors? MarketBeat compares Ascentage Pharma Group International with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ascentage Pharma Group International include Centessa Pharmaceuticals (CNTA), Regencell Bioscience (RGC), Cogent Biosciences (COGT), Belite Bio (BLTE), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry.

How does Ascentage Pharma Group International compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Ascentage Pharma Group International (NASDAQ:AAPG) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

In the previous week, Centessa Pharmaceuticals had 3 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 3 mentions for Centessa Pharmaceuticals and 0 mentions for Ascentage Pharma Group International. Centessa Pharmaceuticals' average media sentiment score of 0.54 beat Ascentage Pharma Group International's score of 0.00 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Centessa Pharmaceuticals	Positive
Ascentage Pharma Group International	Neutral

Ascentage Pharma Group International has higher revenue and earnings than Centessa Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	$15M	419.94	-$197.53M	-$1.79	N/A
Ascentage Pharma Group International	$82.10M	19.43	-$177.71M	N/A	N/A

Centessa Pharmaceuticals has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of -0.05, indicating that its stock price is 105% less volatile than the broader market.

Ascentage Pharma Group International's return on equity of 0.00% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Ascentage Pharma Group International	N/A	N/A	N/A

Centessa Pharmaceuticals currently has a consensus target price of $41.33, suggesting a potential upside of 1.53%. Ascentage Pharma Group International has a consensus target price of $46.43, suggesting a potential upside of 171.83%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, analysts clearly believe Ascentage Pharma Group International is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20

82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 4.1% of Centessa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Ascentage Pharma Group International beats Centessa Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Regencell Bioscience?

Ascentage Pharma Group International (NASDAQ:AAPG) and Regencell Bioscience (NASDAQ:RGC) are both pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
Regencell Bioscience	N/A	N/A	N/A

Ascentage Pharma Group International presently has a consensus price target of $46.43, suggesting a potential upside of 171.83%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, equities analysts plainly believe Ascentage Pharma Group International is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Regencell Bioscience had 18 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 18 mentions for Regencell Bioscience and 0 mentions for Ascentage Pharma Group International. Regencell Bioscience's average media sentiment score of 0.00 beat Ascentage Pharma Group International's score of 0.00 indicating that Regencell Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Ascentage Pharma Group International	Neutral
Regencell Bioscience	Neutral

0.1% of Regencell Bioscience shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Regencell Bioscience has lower revenue, but higher earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$82.10M	19.43	-$177.71M	N/A	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

Ascentage Pharma Group International has a beta of -0.05, meaning that its share price is 105% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market.

Summary

Regencell Bioscience beats Ascentage Pharma Group International on 6 of the 11 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Ascentage Pharma Group International (NASDAQ:AAPG) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

Cogent Biosciences presently has a consensus target price of $43.73, suggesting a potential upside of 16.51%. Ascentage Pharma Group International has a consensus target price of $46.43, suggesting a potential upside of 171.83%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, analysts clearly believe Ascentage Pharma Group International is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20

Cogent Biosciences has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of -0.05, meaning that its share price is 105% less volatile than the broader market.

Ascentage Pharma Group International has higher revenue and earnings than Cogent Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Ascentage Pharma Group International	$82.10M	19.43	-$177.71M	N/A	N/A

Ascentage Pharma Group International's return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Ascentage Pharma Group International	N/A	N/A	N/A

In the previous week, Cogent Biosciences had 2 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 2 mentions for Cogent Biosciences and 0 mentions for Ascentage Pharma Group International. Cogent Biosciences' average media sentiment score of 0.36 beat Ascentage Pharma Group International's score of 0.00 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cogent Biosciences	Neutral
Ascentage Pharma Group International	Neutral

Summary

Ascentage Pharma Group International beats Cogent Biosciences on 6 of the 10 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Ascentage Pharma Group International (NASDAQ:AAPG) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Ascentage Pharma Group International's return on equity of 0.00% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-13.14%	-12.88%
Ascentage Pharma Group International	N/A	N/A	N/A

Belite Bio has higher earnings, but lower revenue than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A
Ascentage Pharma Group International	$82.10M	19.43	-$177.71M	N/A	N/A

Belite Bio currently has a consensus price target of $203.00, indicating a potential upside of 34.64%. Ascentage Pharma Group International has a consensus price target of $46.43, indicating a potential upside of 171.83%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, analysts clearly believe Ascentage Pharma Group International is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20

In the previous week, Belite Bio had 4 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 4 mentions for Belite Bio and 0 mentions for Ascentage Pharma Group International. Belite Bio's average media sentiment score of 0.42 beat Ascentage Pharma Group International's score of 0.00 indicating that Belite Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Belite Bio	Neutral
Ascentage Pharma Group International	Neutral

Belite Bio has a beta of -1.24, meaning that its stock price is 224% less volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of -0.05, meaning that its stock price is 105% less volatile than the broader market.

0.5% of Belite Bio shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Ascentage Pharma Group International beats Belite Bio on 8 of the 13 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Scholar Rock?

Ascentage Pharma Group International (NASDAQ:AAPG) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

Ascentage Pharma Group International's return on equity of 0.00% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
Scholar Rock	N/A	-163.52%	-96.67%

Ascentage Pharma Group International has a beta of -0.05, suggesting that its stock price is 105% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market.

In the previous week, Scholar Rock had 2 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 2 mentions for Scholar Rock and 0 mentions for Ascentage Pharma Group International. Scholar Rock's average media sentiment score of 1.15 beat Ascentage Pharma Group International's score of 0.00 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Overall Sentiment
Ascentage Pharma Group International	Neutral
Scholar Rock	Positive

91.1% of Scholar Rock shares are owned by institutional investors. 13.3% of Scholar Rock shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Ascentage Pharma Group International presently has a consensus price target of $46.43, suggesting a potential upside of 171.83%. Scholar Rock has a consensus price target of $56.00, suggesting a potential upside of 7.01%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, equities analysts plainly believe Ascentage Pharma Group International is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

Ascentage Pharma Group International has higher revenue and earnings than Scholar Rock.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$82.10M	19.43	-$177.71M	N/A	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

Summary

Scholar Rock beats Ascentage Pharma Group International on 7 of the 13 factors compared between the two stocks.

Get Ascentage Pharma Group International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AAPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AAPG vs. The Competition

Export

Metric	Ascentage Pharma Group International	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.59B	$3.49B	$6.74B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	N/A	20.50	25.14	23.95
Price / Sales	19.43	328.65	531.55	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	8.37	8.26	10.67	6.41
Net Income	-$177.71M	$23.91M	$3.56B	$337.14M
7 Day Performance	-0.23%	2.12%	0.98%	-1.06%
1 Month Performance	-18.71%	2.40%	0.78%	0.49%
1 Year Performance	-57.29%	57.09%	30.24%	28.43%

Ascentage Pharma Group International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AAPG Ascentage Pharma Group International	3.7997 of 5 stars	$17.08 +0.4%	$46.43 +171.8%	-57.0%	$1.59B	$82.10M	N/A	600
CNTA Centessa Pharmaceuticals	1.4099 of 5 stars	$40.02 flat	$41.33 +3.3%	+186.7%	$6.19B	$15M	N/A	200	High Trading Volume
RGC Regencell Bioscience	0.52 of 5 stars	$12.01 flat	N/A	-62.7%	$5.94B	N/A	N/A	10	Gap Down High Trading Volume
COGT Cogent Biosciences	1.7805 of 5 stars	$34.54 flat	$43.73 +26.6%	+418.4%	$5.90B	N/A	N/A	80	High Trading Volume
BLTE Belite Bio	3.1287 of 5 stars	$146.12 flat	$203.00 +38.9%	+152.6%	$5.86B	N/A	N/A	10	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AAPG) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ascentage Pharma Group International (AAPG) Competitors

AAPG vs. CNTA, RGC, COGT, BLTE, and SRRK

How does Ascentage Pharma Group International compare to Centessa Pharmaceuticals?

Summary

How does Ascentage Pharma Group International compare to Regencell Bioscience?

Summary

How does Ascentage Pharma Group International compare to Cogent Biosciences?

Summary

How does Ascentage Pharma Group International compare to Belite Bio?

Summary

How does Ascentage Pharma Group International compare to Scholar Rock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AAPG vs. The Competition

Ascentage Pharma Group International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ascentage Pharma Group International (AAPG) Competitors

AAPG vs. CNTA, RGC, COGT, BLTE, and SRRK

How does Ascentage Pharma Group International compare to Centessa Pharmaceuticals?

Does the media refer more to CNTA or AAPG?

Which has higher valuation and earnings, CNTA or AAPG?

Which has more risk and volatility, CNTA or AAPG?

Is CNTA or AAPG more profitable?

Do analysts recommend CNTA or AAPG?

Do insiders and institutionals have more ownership in CNTA or AAPG?

Summary

How does Ascentage Pharma Group International compare to Regencell Bioscience?

Is AAPG or RGC more profitable?

Do analysts rate AAPG or RGC?

Does the media refer more to AAPG or RGC?

Do institutionals and insiders have more ownership in AAPG or RGC?

Which has higher valuation & earnings, AAPG or RGC?

Which has more risk and volatility, AAPG or RGC?

Summary

How does Ascentage Pharma Group International compare to Cogent Biosciences?

Do analysts prefer COGT or AAPG?

Which has more volatility and risk, COGT or AAPG?

Which has higher valuation and earnings, COGT or AAPG?

Is COGT or AAPG more profitable?

Does the media favor COGT or AAPG?

Summary

How does Ascentage Pharma Group International compare to Belite Bio?

Is BLTE or AAPG more profitable?

Which has stronger valuation & earnings, BLTE or AAPG?

Do analysts recommend BLTE or AAPG?

Does the media prefer BLTE or AAPG?

Which has more volatility & risk, BLTE or AAPG?

Do institutionals and insiders believe in BLTE or AAPG?

Summary

How does Ascentage Pharma Group International compare to Scholar Rock?

Is AAPG or SRRK more profitable?

Which has more risk & volatility, AAPG or SRRK?

Does the media refer more to AAPG or SRRK?

Do institutionals and insiders hold more shares of AAPG or SRRK?

Do analysts recommend AAPG or SRRK?

Which has better valuation and earnings, AAPG or SRRK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AAPG vs. The Competition

Ascentage Pharma Group International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools